Skip to content

D&A at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
$2B+13.1%
The Cooper Companies, Inc. logo
The Cooper Companies, Inc.COO
$95.4M+3.0%
Glaukos logo
GlaukosGKOS
$2.91M+9.7%
Tarsus Pharmaceuticals, Inc. logo
Tarsus Pharmaceuticals, Inc.TARS
$197K-10.5%
Warby Parker logo
Warby ParkerWRBY
$13.77M+13.2%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$123.2M-2.9%

Other financials

Income statement

See full
Revenue$1.2B+9.4%
Operating income$33.0M+140%
Net income-$71.0M+66.5%
EPS (diluted)-$0.20+66.7%

Balance sheet

See full
Cash & equivalents$279.0M+29.8%
Total debt$5.0B+4.3%
Total equity$6.4B+0.3%
Total assets$13.8B+2.6%

Cash flow

See full
Operating cash flow$32.0M+228%
CapEx$100.0M-9.1%
Free cash flow-$68.0M+49.6%

Valuation

See full
Market cap$5.43B+10.2%

Profitability

See full
Operating margin4.4%+2.9pp
Net margin-4.2%-1.3pp
FCF margin-3.4%0.0pp

Returns & leverage

See full
Return on equity-3.4%-0.9pp
Debt / equity0.8×0.0×
Current ratio1.5×0.0×

Where this comes from

Reported directly by Bausch + Lomb in its filing.

Tagged under the XBRL concept us-gaap:DepreciationAndAmortization.

The official record: Bausch + Lomb’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →

Ask your AI about Bausch + Lomb's d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Bausch + Lomb's D&A?
Bausch + Lomb (BLCO) reported D&A of $101M in Q1 2026.
How has Bausch + Lomb's D&A changed year-over-year?
Bausch + Lomb's D&A decreased by 4.7% year-over-year, from $106M to $101M.
What is the long-term trend for Bausch + Lomb's D&A?
Over 4 years (2021 to 2025), Bausch + Lomb's D&A has grown at a 0.4% compound annual growth rate (CAGR), from $415M to $421M.
What does D&A mean?
Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.